Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity.
Levine MZ, Holiday C, Bai Y, Zhong W, Liu F, Jefferson S, Gross FL, Tzeng WP, Fries L, Smith G, Boutet P, Friel D, Innis BL, Mallett CP, Davis CT, Wentworth DE, York IA, Stevens J, Katz JM, Tumpey T. Levine MZ, et al. Among authors: innis bl. Vaccines (Basel). 2022 Nov 1;10(11):1856. doi: 10.3390/vaccines10111856. Vaccines (Basel). 2022. PMID: 36366364 Free PMC article.
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.
Nachbagauer R, Salaun B, Stadlbauer D, Behzadi MA, Friel D, Rajabhathor A, Choi A, Albrecht RA, Debois M, García-Sastre A, Rouxel RN, Sun W, Palese P, Mallett CP, Innis BL, Krammer F, Claeys C. Nachbagauer R, et al. Among authors: innis bl. NPJ Vaccines. 2019 Dec 6;4:51. doi: 10.1038/s41541-019-0147-z. eCollection 2019. NPJ Vaccines. 2019. PMID: 31839997 Free PMC article.
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.
Choi A, Bouzya B, Cortés Franco KD, Stadlbauer D, Rajabhathor A, Rouxel RN, Mainil R, Van der Wielen M, Palese P, García-Sastre A, Innis BL, Krammer F, Schotsaert M, Mallett CP, Nachbagauer R. Choi A, et al. Among authors: innis bl. Immunohorizons. 2019 Apr 1;3(4):133-148. doi: 10.4049/immunohorizons.1900022. Immunohorizons. 2019. PMID: 31032479 Free PMC article.
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, Nachbagauer R, Palese P, Solórzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, Rouxel RN, Salaun B, Vantomme V, Verheust C, Struyf F. Folschweiller N, et al. Among authors: innis bl. Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21. Lancet Infect Dis. 2022. PMID: 35461522 Clinical Trial.
Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.
Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, Cohet C, Innis BL, Fries LF. Vaughn DW, et al. Among authors: innis bl. Hum Vaccin Immunother. 2014;10(10):2942-57. doi: 10.4161/21645515.2014.972149. Epub 2014 Nov 21. Hum Vaccin Immunother. 2014. PMID: 25483467 Free PMC article. Clinical Trial.
200 results